I contacted Novo Nordisk back in March to tell them about the remarkable effects C-peptide had on reversing complications of Type 1 diabetes. I asked if they would bring the drug to market. A mass of excitement overwhelmed me when I learned about C-peptide missing from insulin all these years. The response from Novo? No thanks, it's not one of our targets. Targets, eh?

C-peptide is a byproduct of the production of insulin. In Type 1 diabetics, the level of C-peptide eventually becomes undetectable due to the body not making any insulin of its own. Long-term complications of diabetes frequently develop despite insulin therapy and optimal blood glucose control. C-peptide could quite possibly be the missing link in perfect diabetes control. I sent the following document to Novo Nordisk and asked them to make C-peptide available to reverse and ameliorate renal and nerve dysfunction for Type 1 diabetics. Read the document and see for yourself the eye-popping beneficial results C-peptide offers Type 1 diabetics. I received it directly from Dr. Wahren, lead researcher for C-peptide.

After 5 months consideration, Novo called me back. They said C-peptide is not a target for their company. I understand and now Levemir is not a target in my diabetes control, either. For all the Type 1 diabetics out there controlling your sugars with insulin not really made with you in mind -- do you understand why Novo does not wish to develop this critically important treatment? I guess insulin is good enough, right? Wrong. It's a tough job but somebody's got to do it. Just not Novo. When you are in the business of diabusiness -- no thank you says so much about what could potentially hurt your business.